Sava Secures $19M In Series A Round

Founded in 2019 by Imperial College bioengineers Renato Circi and Rafaël Michali, Sava aims to transform preventive and personalized healthcare.

Their core innovation is a next-gen, pain-free wearable that uses a proprietary biosensor to detect multiple biomarkers just beneath the skin in real time—delivering continuous molecular insights directly to a smartphone. This makes it a more affordable and longer-lasting alternative to existing microsensor devices.

In a recent independent clinical trial conducted across Oxford and Cambridge, Sava’s device showed reliable glucose monitoring for up to 10 days outperforming current tech, which typically lasts five days at most. The trial involved 50 patients with Type 1 and insulin-dependent Type 2 diabetes, with the first 25 yielding strong preliminary results.

Read Also - Packwise Raises Growth Capital For Transatlantic Push And Next-Gen Container Tech

Designed in partnership with leading clinicians and regulators the trial paves the way for Sava’s pivotal study scheduled for next year.

Rafaël Michali, co-founder and co-CEO of Sava explained: This clinical trial marks a pivotal moment not just for Sava but for the future of biosensing and personalised healthcare. The data generated so far has shown that our technology has the potential to match the performance of leading CGMs in the market today, without the invasiveness or high cost of filament-based systems. It paves the way for a completely novel approach to biosensing that can redefine the way we approach not only chronic disease management, but any health goal.

Sava’s device aims to revolutionize diabetes care by overcoming the main hurdles to CGM adoption: pain, high costs, and limited access. Currently, just 1% of people with diabetes use CGMs—yet this niche market already generates over $11 billion annually, growing at 10% per year.

With its pain-free, affordable, and scalable solution, Sava is positioned to dramatically broaden access to continuous glucose monitoring and redefine diabetes management.

The $19M Series A round was led by Balderton Capital and Pentland Ventures, with new backers Norrsken VC and JamJar Investments joining existing investors True, Italian Founders Fund, Athletico Ventures, and Exceptional Ventures.

Understanding what’s going on in our bodies is the first step to improving our health,

said James Wise, Partner at Balderton, adding: Sava’s innovation has the potential to democratise access to glucose monitoring, as well as many other biomarkers, making them more practical for the millions of people who need them but can’t afford or tolerate the current options. Beyond diabetes, which alone is one of the greatest health challenges of our time, their platform opens the door to an entirely new era of personalised health monitoring.

Glucose monitoring is only the first step for Sava. Its modular, multi-analyte sensing platform can track a variety of biomarkers in real time, paving the way for truly preventative and personalised healthcare.

With growing demand from athletes and health-focused users, Sava is also set to tap into the booming wearables market, projected to exceed $100 billion by 2029.

Renato Circi, co-founder and co-CEO of Sava shared: We have built a modular platform capable of multi-molecule sensing. New molecules will create new use cases. What we’re building here is not just a device, but a whole new technological foundation for personalised healthcare, where anyone can use a biosensor to understand their health in real-time, at a molecular level.

With this latest round, Sava’s total funding now stands at $32 million, supported by top venture capital firms, returning angel investors, and grants from both the EU and UK Government.

Charlie Rubin, Investor at Pentland Ventures, said: With its world-first technology, breakthrough clinical trial results, and new funding, Sava is positioned to lead the next wave of innovation in the $100B+ global health wearables market - beginning with CGM and creating a new market for real-time, multi-biomarker sensing. We are thrilled to be a part of the journey.

The new funding will help Sava grow its expert team, ramp up automated manufacturing to reach launch targets, and fast-track clinical validation of its microsensor technology.

About Sava

SAVA is changing how we understand our health. Using advanced biosensing tech, it reads vital data just beneath the skin—painlessly, in real time, and at low cost—giving people easy access to their body’s information like never before.